Skip to main content
Download PDF
Download ePub
  • Research Article
  • Open access
  • Published:

Interleukin-6 polymorphisms in HCC patients chronically infected with HCV

Infectious Agents and Cancer volume 15, Article number: 21 (2020) Cite this article

Abstract

Hepatocellular carcinoma is a primary liver malignancy in which the risk of development is always multifunctional. Interleukin-6 is a proinflammatory and multifunctional cytokine, which plays an important role in the immune response, haematopoiesis and defence against viral infection. We aimed to evaluate the frequency of Interleukin-6 mutations (rs2069837 and rs17147230) associated with genetic risk of hepatocellular carcinoma in Khyber Pakthunkhwa population. A total of 72 hepatocellular carcinoma cases and 38 controls were included in this study. The genomic DNA was extracted from the peripheral blood cells and Interleukin-6 genotyping was performed using T-ARMS-PCR technique. Our results show a significant increase risk of developing hepatocellular carcinoma with the mutation within Interleukin-6 gene with heterozygous G allele (rs2069837) (OR = 10.667, 95%CI = 3.923–29.001, p = < 0.0001) and heterozygous T allele (rs17147230) (OR = 75.385, 95%CI = 9.797–580.065, p = < 0.0001). However, under recessive gene model the results were insignificant in case of Interleukin-6 rs2069837 (OR = 0.605, 95%CI = 0.217–1.689, p = 0.337), while significant in case of Interleukin-6 rs17147230 (OR = 0.298, 95%CI = 0.121–0.734, p = 0.0085). In conclusion, Interleukin-6 mutation is associated with hepatocellular carcinoma susceptibility. More related studies with other associated interleukins and their whole gene sequencing will be required.

Background

Hepatocellular carcinoma (HCC) is the most common primary liver cancer. In Pakistan, HCC represents the fourth most common malignancy in men and the seventh in woman [1]. Worldwide, HCC is considered the third main cause for cancer death, especially in patients with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection [2, 3]. In advanced stages of HBV and HCV diseases the immune response is often insufficient to eradicate the viruses, resulting in chronic liver inflammation through a lifelong host-virus interaction. There is growing evidence that chronic inflammation is involved in the progression of cancer. HCC occurrence varies greatly around the world but HCC is found 3–4 times more frequent in males often than females [4]. This difference in gender may be due to lifestyle-related risk factors for HCC, such as alcohol consumption and smoking. Though, sex hormones and X-linked chromosome hereditary factors may also be important, because males are more vulnerable to HCC than females [5]. It has also been demonstrated that host genetic factors, such as single nucleotide polymorphisms (SNPs), could affect individual susceptibility to HCC [6]. The risk factors which include diabetes, obesity and environmental factors like carcinogens are observed highly variable among the HCC patients, which are mostly associated with the race or ethnic groups and geographic region of the infected individuals. However, majority of these risk factors progress to the development of cirrhosis, which is present in almost 80–90% of patients with HCC [7].

Macrophages and lymphocytes produce interleukins (ILs) and other cytokines that regulate antiviral activity genome-wide. Association of SNPs at various ILs have shown positive influence on chronic HCV leading to HCC development [8]. Various ILs and their respective SNPs have shown positive association with HCV treatment and susceptibility, which leads to cirrhosis, fibrosis and HCC development. Cytokines act in a very complex and composed system in which they initiate or block their own synthesis and additionally, different cytokines and cytokine receptors synthesis [9]. In any case, there is growing evidence concerning the role of hereditary components to imbalance pro-inflammatory and anti-inflammatory cytokine profile that may influence the clinical result and severity of Hepatitis C. The balance of pro-inflammatory and anti-inflammatory cytokines may change the benefits of antiviral treatment, thereby affecting the outcome of disease, for example, the clearance of HCV after severe infection or the development of liver disease [10]. However, there is no straightforward evidence about the association of ILs and their respective SNPs with viral infections within ethnic groups of Khyber Pakthunkhwa (KP) population.

Interleukin-6 (IL-6) is a pro-inflammatory and multifunctional cytokine, which is located at 7p21 chromosome. Hepatic response to infections and systemic inflammation is the key function of IL-6 [11]. Indeed, IL-6 produced by B cells, T cells, macrophages, and fibroblasts have a pleiotropic effect on inflammation, immune response, and haematopoiesis [12]. Polymorphisms in IL-6 promoter region were appeared to be involved in the pathogenesis of some immune mediated diseases [13]. The association of SNPs within the IL-6 gene have shown different response to HCC and proliferation with respect to alcoholic, HBV and HCV infections [14]. However, there is still a gap to understand the association of IL-6 SNPs within ethnic groups, including Pakistani population with HCC progression and proliferation in chronic HBV and HCV infections. Therefore, understanding the HCC development in chronically HCV infected individuals and their associated risk factors would be a great importance in HCC progression. ILs and other genetic factors including microRNAs and mitochondrial DNA association with treatment regimen have great importance nowadays. However, there is no such evidence about the association of IL-6 SNPs and HCC patients in KP population, which are chronically infected with HCV. In the present study, we will explain the association of IL-6 SNPs with HCC susceptibility in chronically HCV infected individuals of KP-Pakistan.

Methods

Demographic data and blood sampling

Demographic data and blood samples were collected from 80 HCV related HCC and 50 HCV infected patients at Leady Ready Hospital and Hayatabad Medical Complex Peshawar, KP, Pakistan during January to December 2018. Based on our study inclusion/exclusion criteria (HCV leading to HCC), 72 out of 80 HCC patient and 38 out of 50 HCV infected samples as control were selected for further analysis.

HCV screening and RT-PCR

All the samples were confirmed for HCV using Immuno-Chromatographic Test (ICT) and PCR. Briefly, serum was extracted and applied for ICT strips using standard procedure and protocol. All the ICT positive HCV samples were further processed for viral RNA extraction using Ribo Virus (Sacace Biotechnologies, Italy) as manufacturer’s instructions. Active-HCV infection was confirmed through Bio-Rad PCR machine using commercially available InnuPrep®/RoboGene® HCV RNA purification and Quantification kit (Aj-Roboscreen Germany) [15].

Genomic DNA extraction and T-ARMS PCR for SNP detection

After confirmation of HCV infection, the blood samples were subjected to genomic DNA extraction using standard protocol [16]. ARMS-PCR genotyping method was used to detect the SNP, using specific pairs of primers for IL-6 rs2069837 and rs17147230 (Table 1). The ARMS PCR reaction was conducted in 10 μL volume containing DNA sample 1 μL, 5 μL of Master mix, 0.5 μL of forward and reverse primer, and 3 μL ddH2O. The PCR amplification was done at, initial denaturation 94 °C for 5 min, followed by 35 cycles at 94 °C for 15 s, 57 °C for 15 s and 72 °C for 30 s and final extension at 72 °C for 7 min.

Table 1 Specific primers for IL-6 regions
Full size table

Gel electrophoresis and data analysis

The ARMS-PCR products were analysed on 2% Agarose gel, comparing with 100 bp DNA Ladder (Thermo Scientific). The odds ratios with corresponding 95% confidence intervals were used to assess association between genetic polymorphism in IL-6 and HCV leading to HCC. A p-value < 0.05 was considered statistically significant. Statistical analysis was performed using online MedCalc software. Homozygosis and heterozygosis between the HCC cases and control group were directly counted.

Results

Occurrence of HCC in different age groups

The study was conducted to understand the association of IL-6 SNPs in HCC patients chronically infected with HCV. Out of 80 HCC and 50 HCV infected patients as control, 72 HCC and 38 HCV were enrolled in this study as our study exclusion/inclusion criteria (HCV leading to HCC). Based on age, patients’ samples were categorized in four different age groups. The age groups of HCC patients were categorized in 31–40 years, 41–50 years, 51–60 years and above 60 years. The occurrence of HCC was noted high in above 60 years (52.8%) followed by 51–60 years (30.6%) (Fig. 1).

Fig. 1
figure 1

Occurrence of HCC in different age groups

Full size image

IL-6 genotyping for region rs2069837 and rs17147230

All the HCC and control samples were processed for IL-6 rs2069837 and rs17147230 using T-ARMS PCR. The sample gels pictures for regions rs2069837 and rs17147230, respectively, show the SNPs genotypes (Fig. 2a-b and Fig. 3a-b).

Fig. 2
figure 2

Sample Gel picture of IL-6 region rs2069837. A region of 432 bp were amplified containing the rs2069837 as control (a, lane 1 and 2). For SNP genotyping Forward Outer plus Inner Reverse primers of 117 bp and Inner Forward plus Reverse Outer of 321 bp product sizes were amplified. The AG shows heterozygous mutation (b, lane 1,2,3,5 and 6), while GG shows homozygous mutation, lane 4)

Full size image
Fig. 3
figure 3

Sample Gel picture of IL-6 region rs17147230: A region of 226 bp containing the rs17147230 were amplified as control (b, lane 1–4). For mutation detection, Forward Outer plus Inner Reverse primers and Inner Forward plus Reverse Outer primers of products sizes 173 bp and 97 bp, respectively, were amplified. The A/T shows heterozygous mutation (a, lane 1–4)

Full size image

Frequencies of alleles/genotypes associated with HCC

The molecular analysis shows that the wild A allele of both the regions (rs2069837 and rs17147230) was present in higher frequencies (71.0, 63.0%) in the control group than in the HCV leading to HCC cases (53.0, 53.0%), respectively. Consequently, there was a significant increase in HCC in HCV infected individuals carrying G allele (rs2069837) (OR = 2.196, 95% CI = 1.213–3.978, p = 0.0094) and T allele (rs17147230) (OR = 1.432, 95% CI = 0.817–2.509, p = 0.210) (Tables 2 and 3). Similarly, the genotype analysis revealed that AA genotype of both the regions was detected in more individuals in control group (63.0%) compared with HCC cases (19.0%). A significant increase in the risk of HCC was noted with the mutations and the heterozygous G allele (rs2069837) (OR = 10.667, 95%CI = 3.923–29.001, p = < 0.0001) and T allele (rs17147230) (OR = 75.385, 95%CI = 9.797–580.065, p = < 0.0001) carriers were noted to have a significantly higher risk of HCC (Tables 2 and 3). However, under recessive gene model the results were insignificant in case of IL-6 rs2069837 (OR = 0.605, 95%CI = 0.217–1.689, p = 0.337) (Table 2), while significant in case of IL-6 rs17147230 (OR = 0.298, 95%CI = 0.121–0.734, p = 0.0085) (Table 3).

Table 2 Statistical relationship and Allele/Genotypes frequencies analysis of rs2069837 Loci in HCC cases and control subjects
Full size table
Table 3 Statistical relationship and Allele/Genotypes frequencies analysis of rs17147230 Loci in HCC cases and control subjects
Full size table

Discussion

Cytokines are important biological molecules that act as soluble mediators of the immune response. IL-6 is produced by numerous typical cells such as mononuclear phagocytes, endothelial cells, T- and B-lymphocytes, fibroblasts, astrocytes and medullary stromal cells. IL-6 induces the synthesis of acute phase proteins, represents the main activator of the differentiation of B lymphocytes into plasma cells and induces the cell cycle in megakaryocytopoietic and myelopoietic progenitors [12].

IL-6 is a pleiotropic cytokine known to play a crucial role in the regulation of the biological effects of hepatocytes and its dysregulated expression has a pathological effect on chronic inflammation, immune response and haematopoiesis.

Chronic inflammation is the result of inflammatory cells recruited to the inflamed site, associated with induction of anti-apoptotic mechanisms [17]. IL-6 plays a key role in this process, due to its dual pro and anti-inflammatory cytokine capacity, which in turn supports cell growth and anti-apoptotic activities that accompany chronic inflammation [18]. Chronic HCV infection is associated with variable outcome, ranging from simple hepatic damage, to cirrhosis and HCC [19]. Furthermore, HCV infection has been shown to play an important role in development of liver disease via the IL-6/STAT3 pathway [20]. Recently, an interesting study has identified a set of immune mediators (cytokines, growth factors, and apoptosis markers) whose levels were significantly higher in serum of patients who eventually developed de novo HCC compared with controls. An higher value of 9 inflammatory cytokines (MIG, IL22, TRAIL, APRIL, VEGF, IL3, TWEAK, SCF, IL21), assumes a possible role in carcinogenesis. These results potentially suggest that before immune changes occur, due to HCV targeting by DAAs, individuals who developed HCC already expressed a differential pattern of immune mediators, possibly induced by ongoing carcinogenic or precarcinogenic activity [21].

Several studies have been conducted to investigate the correlation between the different host genetic factors and the susceptibility of HCV infection in different populations [22,23,24,25].

IL-6 was the most reported gene to be associated with HCV infection or HCC development in chronic HCV patients. The SNPs of the IL-6 gene have been reported to influence the histologic progression and clinical outcomes of HCV patients [26,27,28] but there is a great disparity in the correlation between IL-6 gene polymorphisms and hepatitis-related HCC according to the literature [29, 30].

Polymorphisms of the IL-6 gene is associated with HCV viral clearance, and the serum IL-6 level shows an increase in HCV infected persons [31] and it has been suggested as biomarker for poor prognosis of patients with HCC [32].

IL-6 gene plays an important role in human immunologic antagonism, therefore the genetic variations in the IL-6 gene are commonly studied in HCV infected persons [33]. A few investigations have cited the connection between different ILs gene mutations and incidence of HCV-related HCC progression [28, 34,35,36]. Thus, the aim of this study is to verify the relationship of IL-6 gene polymorphism (rs2069837 and rs17147230) with HCV leading to HCC.

Our results indicated that there was a significant HCC increase in HCV infected individuals carrying mutated heterozygous G allele (rs2069837) and T allele (rs17147230) (Tables 2 and 3). However, under recessive gene model the results were insignificant in case of IL-6 rs2069837, while significant in case of IL-6 rs17147230. Thus, IL-6 SNPs may be a possible risk factor to contribute to the susceptibility to liver diseases. The genetic polymorphisms of the interleukin genes could influence the infection, pathogenesis and treatment effect of HCV patients [28, 37]. Indeed, the dysregulated synthesis of IL-6 activates downstream immune and oxidative stress signaling to exacerbate inflammation infiltration and eventually leads to the onset or development of liver diseases [30]. Furthermore, elevated IL-6 levels in HCV infected patients are associated with disease progression, probably due to the IL-6 ability to decrease apoptosis of HCC cells, thereby conferring survival advantage for cancer cells [28]. Moreover, IL-6 was linked with natural killer cell dysfunction, which may provide a mechanism of tumor escape from immune surveillance [38].

Conclusions

HCC pathogenesis is a multistep process involving the progressive accumulation of genetic and epigenetic alterations. Molecular pathogenesis is extremely complex and heterogeneous and this reflex the lack of specific molecular characterization. Thus, direct molecular or epigenetic research is needed to investigate the actual scenario of HCC in the context of HCV viral infection, that leading liver to steatosis, cirrhosis, or eventually HCC.

In our study we observed a significant association for both the SNPs within IL-6 with HCC susceptibility. More intensive investigations will be required to explore the possible involvement of IL-6 polymorphisms to HCC progression in HCV infected individuals, with the aim of future application of SNPs as biomarkers for the risk stratification of HCC onset and the prediction of the prognosis, as well as to evaluate the clinical progress of the disease.

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Abbreviations

CI:

Confidence interval

DAAs:

Direct-acting antivirals

ddH2O:

Double-distilled water

DNA:

Deoxyribonucleic acid

GCP:

Good clinical practice

HBV:

Hepatitis B virus

HCV:

Hepatitis C Virus

IBGE:

Institute of Biotechnology and Genetic Engineering

ICH:

The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use

ICT:

Immunochromatographic test

IL-6:

Interleukin-6

KP:

Khyber Pakhtunkhwa

OD:

Odds ratio

SNPs:

Single nucleotide polymorphisms

STAT3:

Signal transducer and activator of transcription 3 protein

T-ARMS-PCR:

Tetra-primer amplification refractory mutation system based polymerase chain reaction

UAP:

University of Agriculture Peshawar

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424. https://doi.org/10.3322/caac.21492.

    Article  PubMed  Google Scholar 

  2. Raza SA, Clifford GM, Franceschi S. Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. Br J Cancer. 2007;96:1127–34. https://doi.org/10.1038/sj.bjc.6603649.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529–38. https://doi.org/10.1016/j.jhep.2006.05.013.

    Article  PubMed  Google Scholar 

  4. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010. https://doi.org/10.1016/S1590-8658(10)60507-5.

  5. Kirsch-Volders M, Bonassi S, Herceg Z, Hirvonen A, Möller L, Phillips DH. Gender-related differences in response to mutagens and carcinogens. Mutagenesis. 2010. https://doi.org/10.1093/mutage/geq008.

  6. Dragani TA. Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol. 2010;52:252–7. https://doi.org/10.1016/j.jhep.2009.11.015.

    Article  CAS  PubMed  Google Scholar 

  7. Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology Elsevier Inc. 2011;140:1182–8. https://doi.org/10.1053/j.gastro.2010.12.032.

    Article  Google Scholar 

  8. Neukam K, Camacho A, Caruz A, Rallón N, Torres-Cornejo A, Rockstroh JK, et al. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. J Hepatol. 2012;56:788–94. https://doi.org/10.1016/j.jhep.2011.11.008.

    Article  CAS  PubMed  Google Scholar 

  9. Wojdasiewicz P, Poniatowski ŁA, Szukiewicz D. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediat Inflamm. 2014. https://doi.org/10.1155/2014/561459.

  10. Fallahi P, Ferri C, Ferrari SM, Corrado A, Sansonno D, Antonelli A. Cytokines and HCV-related disorders. Clin Dev Immunol. 2012. https://doi.org/10.1155/2012/468107.

  11. Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. Elsevier Inc. 2014;141:125–9. https://doi.org/10.1016/j.pharmthera.2013.09.004.

    Article  CAS  Google Scholar 

  12. Tanaka T, Narazaki M, Kishimoto T. Il-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014. https://doi.org/10.1101/cshperspect.a016295.

  13. Giannitrapani L, Soresi M, Balasus D, Licata A, Montalto G. Genetic association of interleukin-6 polymorphism (−174 G/C) with chronic liver diseases and hepatocellular carcinoma. World J Gastroenterol. 2013. https://doi.org/10.3748/wjg.v19.i16.2449.

  14. Wong VW-S, Yu J, Cheng AS-L, Wong GL-H, Chan H-Y, Chu ES-H, et al. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer. 2009;124:2766–70. https://doi.org/10.1002/ijc.24281.

    Article  CAS  PubMed  Google Scholar 

  15. Khan NU, Ali I, Ahmad NU, Iqbal A, Rehman LU, Munir I, et al. Prevalence of active HCV infection among the blood donors of Khyber Pakhtunkwa and FATA region of Pakistan and evaluation of the screening tests for anti-HCV. Virol J. BioMed Central Ltd. 2011;8:154. https://doi.org/10.1186/1743-422X-8-154.

    Article  Google Scholar 

  16. V IM, Esmailizadeh AK. Extraction of DNA from Whole Blood Stored at 4oC for Long Period. J Biol Methods. 2010. https://doi.org/10.1385/1-59259-384-4:29.

  17. Smith AJP, D’Aiuto F, Palmen J, Cooper JA, Samuel J, Thompson S, et al. Association of Serum Interleukin-6 Concentration with a Functional IL6 −6331T>C Polymorphism. Clin Chem. 2008;54(5):841–50. https://doi.org/10.1373/clinchem.2007.098608.

    Article  CAS  PubMed  Google Scholar 

  18. Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 2002;13(4):357–68. https://doi.org/10.1016/S1359-6101(02)00027-8.

    Article  CAS  PubMed  Google Scholar 

  19. Walter SR, Thein HH, Gidding HF, Amin J, Law MG, George J, Dore GJ. Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C. J Gastroenterol Hepatol. 2011;26(12):1757–64. https://doi.org/10.1111/j.1440-1746.2011.06785.x.

    Article  PubMed  Google Scholar 

  20. Dai CY, Tsai YS, Chou WW, et al. The IL-6/STAT3 pathway upregulates microRNA-125b expression in hepatitis C virus infection. Oncotarget. 2018;9:11291–302.

    PubMed  PubMed Central  Google Scholar 

  21. Debes JD, van Tilborg M, Groothuismink ZMA, Hansen BE, Schulze Zur Wiesch J, von Felden J, de Knegt RJ, Boonstra A. Levels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated With Direct-Acting Antivirals. Gastroenterology. 2018;154(3):515–7.e3. https://doi.org/10.1053/j.gastro.2017.10.035.

    Article  CAS  PubMed  Google Scholar 

  22. Steba GS, Koekkoek SM, Tanck MWT, Vanhommerig JW, Meer JTM, Brinkman K, et al. SNP rs688 within the low-density lipoprotein receptor (LDL-R) gene associates with HCV susceptibility. Liver Int. 2018. https://doi.org/10.1111/liv.13978.

  23. Swiatek-Koscielna B, Kaluzna E, Strauss E, Nowak J, Bereszynska I, Gowin E, et al. Januszkiewicz-Lewandowska D. prevalence of IFNL3 rs4803217 single nucleotide polymorphism and clinical course of chronic hepatitis C. World J Gastroenterol. 2017;23(21):3815–24. https://doi.org/10.3748/wjg.v23.i21.3815.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Zhang AM, Ma K, Song Y, Wang B, Feng Y, et al. Genetic polymorphisms of the IFNlambda genes are associated with biochemical features in Han Chinese with HCV infection from Yunnan Province. Chin Infect Genet Evol. 2014;21:161–5 https://doi.org/10.1016/j.meegid. 2013.11.013.

    Article  Google Scholar 

  25. Zhang A-M, Zhang C-L, Song Y, Zhao P, Feng Y, Wang B, Xia X. Genetic variations of the NPC1L1 gene associated with hepatitis C virus (HCV) infection and biochemical characteristics of HCV patients in China. Int J Infect Dis. 2016;53:6–11 https://doi.org/10.1016/j.ijid. 2016.10.007.

    Article  CAS  PubMed  Google Scholar 

  26. Falleti E, Fabris C, Vandelli C, Colletta C, Cussigh A, Smirne C, et al. Genetic polymorphisms of interleukin-6 modulate fibrosis progression in mild chronic hepatitis C. Hum Immunol. 2010;71(10):999–1004. https://doi.org/10.1016/j.humimm.2010.06.006.

    Article  CAS  PubMed  Google Scholar 

  27. Bogdanović Z, Marinović-Terzić I, Kuret S, Jerončić A, Bradarić N, Forempoher G, et al. The impact of IL-6 and IL-28B gene polymorphisms on treatment outcome of chronic hepatitis C infection among intravenous drug users in Croatia. PeerJ. 2016;4:e2576. https://doi.org/10.7717/peerj.2576.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Sghaier I, Mouelhi L, Rabia NA, Alsaleh BR, Ghazoueni E, Almawi WY, Loueslati BY. Genetic variants in IL-6 and IL-10 genes and susceptibility to hepatocellular carcinoma in HCV infected patients. Cytokine. 2017;89:62–7. https://doi.org/10.1016/j.cyto.2016.10.004.

    Article  CAS  PubMed  Google Scholar 

  29. Dondeti MF, El-Maadawy EA, Talaat RM. Hepatitis-related hepatocellular carcinoma: insights into cytokine gene polymorphisms. World J Gastroenterol. 2016;22(30):6800–16. https://doi.org/10.3748/wjg.v22.i30.6800.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Wang X, Yan Z, Ye Q. Interleukin-6 gene polymorphisms and susceptibility to liver diseases: a meta-analysis. Medicine (Baltimore). 2019;98(50):e18408. https://doi.org/10.1097/MD.%200000000000018408.

    Article  CAS  Google Scholar 

  31. Tarrago, A. M., Costa, A. G., Pimentel, J. P., Gomes, S. T., Freitas, F. B., Lalwani, P., et al. Combined impact of hepatitis C virus genotype 1 and interleukin-6 and tumor necrosis factor-alpha polymorphisms on serum levels of pro-inflammatory cytokines in Brazilian HCV-infected patients. Hum Immunol 2014; 75( 11), 1075–1083. https://doi.org/10.1016/j.humimm. 2014. 08. 198.

  32. Shao YY, Lin H, Li YS, et al. High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma. Jpn J Clin Oncol. 2017;47:949–53. https://doi.org/10.1093/jjco/hyx103.

    Article  PubMed  Google Scholar 

  33. Cussigh A., Falleti E., Fabris C., Bitetto D., Cmet S., Fontanini E et al. Interleukin 6 promoter polymorphisms influence the outcome of chronic hepatitis C. Immunogenetics 2011; 63( 1), 33–41. https://doi.org/10.1007/s00251-010-0491-7.

  34. Zheng X, Han C, Shan R, Zhang H, Zheng Z, Liu Y, Wang A. Association of interleukin-6 polymorphisms with susceptibility to hepatocellular carcinoma. Int J Clin Exp Med. 2015;8(4):6252–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Naseem S, Manzoor S, Javed A, Abbas S. Interleukin-6 rescues lymphocyte from apoptosis and exhaustion induced by chronic hepatitis C virus infection. Viral Immunol. 2018 Nov;31(9):624–31. https://doi.org/10.1089/vim.2018.0045.

    Article  CAS  PubMed  Google Scholar 

  36. Nawaz R, Zahid S, Idrees M, Rafique S, Shahid M, Ahad A, Amin I, Almas I, Afzal S. HCV-induced regulatory alterations of IL-1β, IL-6, TNF-α, and IFN-ϒ operative, leading liver en-route to non-alcoholic steatohepatitis. Inflamm Res. 2017 Jun;66(6):477–86. https://doi.org/10.1007/s00011-017-1029-3.

    Article  CAS  PubMed  Google Scholar 

  37. Song Y, Yang X, Shen Y, Wang Y, Xia X, Zhang AM. STAT3 signaling pathway plays importantly genetic and functional roles in HCV infection. Mol Genet Genomic Med. 2019 Jun;20:e821. https://doi.org/10.1002/mgg3.821.

    Article  CAS  Google Scholar 

  38. Martin M, Herceg Z. From hepatitis to hepatocellular carcinoma: a proposed model for cross-talk between inflammation and epigenetic mechanisms. Genome Med. 2012 Jan 31;4(1):8. https://doi.org/10.1186/gm307.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Institute of Biotechnology and Genetic Engineering (Health Division), The University of Agriculture, Peshawar, Pakistan

    Faisal Adnan, Najeeb Ullah Khan & Aqib Iqbal

  2. Department of Biosciences, COMSATs University, Islamabad, Pakistan

    Ijaz Ali

  3. UOC Clinical Pathology, AORN Sant’Anna e San Sebastiano, Caserta, Italy

    Arnolfo Petruzziello

  4. Unit of Molecular Biology and Viral Oncology, Istituto Nazionale Tumori, IRCCS Fondazione Pascale, Naples, Italy

    Rocco Sabatino

  5. SSD Transfusion medicine, Istituto Nazionale Tumori – IRCCS Fondazione “G. Pascale”, Naples, Italy

    Annunziata Guzzo

  6. Hematology-Oncology and stem cell transplantation Unit, IRCCS Fondazione “G. Pascale”, Naples, Italy

    Giovanna Loquercio

  7. Scientific Directorate, Istituto Nazionale Tumori, IRCCS Fondazione “G. Pascale”, Naples, Italy

    Gerardo Botti

  8. Department of Zoology, University of Peshawar, Peshawar, KP, Pakistan

    Sanaullah Khan

  9. Department of community medicine, Khyber Medical Collage, Peshawar, Pakistan

    Muhammad Naeem

  10. Department of Zoology, Islamia College, Peshawar, Pakistan

    Muhammad Ismail Khan

Authors
  1. Faisal Adnan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Najeeb Ullah Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aqib Iqbal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ijaz Ali
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Arnolfo Petruzziello
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rocco Sabatino
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Annunziata Guzzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Giovanna Loquercio
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Gerardo Botti
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Sanaullah Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Muhammad Naeem
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Muhammad Ismail Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

NUK designed and supervised the study, FA collected the data, AP, RS, AG, GL, SK and MN streamlined the study and helped in writing the manuscript, MIK and GB supervised the study. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Najeeb Ullah Khan, Arnolfo Petruzziello or Annunziata Guzzo.

Ethics declarations

Ethics approval and consent to participate

The Ethic Committee of the IBGE, UAP granted approval for the study that was conducted according the principles of ICH-GCP and Declaration of Helsinki.

Consent for publication

Not applicable.

Competing interests

The authors declare they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adnan, F., Khan, N.U., Iqbal, A. et al. Interleukin-6 polymorphisms in HCC patients chronically infected with HCV. Infect Agents Cancer 15, 21 (2020). https://doi.org/10.1186/s13027-020-00285-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13027-020-00285-9

Keywords

Infectious Agents and Cancer

ISSN: 1750-9378

Contact us